Immune checkpoint inhibitors consist in antibodies used in immunotherapy against cancer. One of their targets is the programmed cell death-1 (PD-1) receptor, which is important in Maintaining self-tolerance. However, this mechanism is associated with a risk for immune-related adverse events potentially affecting multiple organs, including the endocrine system. We describe the unusual case of a patient who, after 18 months of treatment withan immune checkpoint inhibitor, debuted with diabetic ketoacidosis.

Gabriela Meneses is a Chilean Internal Medicine Physician with clinical experience in hospital and outpatient care. She currently works at Navy Hospital in Viña del Mar, Chile, where she has served as an Internal Medicine Physician since April 2023. Her medical training includes a Medical Degree from Universidad Nacional Andrés Bello, Chile (2007-2015), followed by postgraduate training in Internal Medicine at Universidad de Valparaíso, Chile (2020–2023). Her professional interests include internal medicine, diabetes, endocrinology, chronic disease management, and comprehensive patient care. She has experience caring for patients with acute and complex medical conditions, as well as managing chronic diseases in ambulatory settings. she has also contributed to medical research and scientific publications. Her published work includes “Diabetic Ketoacidosis as Debut of Immune-Mediated Diabetes Mellitus in a Patient in Treatment with Immune Checkpoint Inhibitors,” published in September 2023 in the Chilean Journal of Endocrinology and Diabetes.